Genmab A (GMAB) Non-Current Deffered Revenue (2023 - 2025)
Genmab A's Non-Current Deffered Revenue history spans 3 years, with the latest figure at $95.0 million for Q4 2025.
- For Q4 2025, Non-Current Deffered Revenue rose 41.79% year-over-year to $95.0 million; the TTM value through Dec 2025 reached $95.0 million, up 41.79%, while the annual FY2025 figure was $95.0 million, 41.79% up from the prior year.
- Non-Current Deffered Revenue reached $95.0 million in Q4 2025 per GMAB's latest filing, up from $67.0 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $95.0 million in Q4 2025 to a low of $67.0 million in Q4 2024.
- Average Non-Current Deffered Revenue over 3 years is $77.7 million, with a median of $71.0 million recorded in 2023.
- Peak YoY movement for Non-Current Deffered Revenue: decreased 5.63% in 2024, then soared 41.79% in 2025.
- A 3-year view of Non-Current Deffered Revenue shows it stood at $71.0 million in 2023, then decreased by 5.63% to $67.0 million in 2024, then surged by 41.79% to $95.0 million in 2025.
- Per Business Quant, the three most recent readings for GMAB's Non-Current Deffered Revenue are $95.0 million (Q4 2025), $67.0 million (Q4 2024), and $71.0 million (Q4 2023).